Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kayvon Modjarrad

Showing results (61-70 of 135) with videos related to

Pageof 14
Sort By:
Emerging Infectious Diseases|April 20, 2019
Zika Virus in Rectal Swab SamplesCamila Helena Aguiar Bôtto-Menezes, Armando Menezes Neto, Guilherme Amaral Calvet, et al.
Ebiomedicine|October 4, 2023
Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccineYifan Li, Mélanie Merbah, Suzanne Wollen-Roberts, et al.
Infectious Diseases and Therapy|July 1, 2025
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 TrialOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Vaccine|February 25, 2025
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years oldOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Plos One|March 30, 2021
Clinical laboratory reference values in adults in Kisumu County, Western Kenya; hematology, chemistry and CD4Valentine Sing'oei, Jew Ochola, John Owuoth, et al.
Vaccines|February 24, 2024
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 TrialJuleen Gayed, Oyeniyi Diya, Francine S Lowry, et al.
NPJ Vaccines|December 14, 2021
SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responsesJoshua M Carmen, Shikha Shrivastava, Zhongyan Lu, et al.
Journal of Neuroinflammation|February 8, 2022
Neurocognitive impact of Zika virus infection in adult rhesus macaquesDenise C Hsu, Kesara Chumpolkulwong, Michael J Corley, et al.
Memorias Do Instituto Oswaldo Cruz|January 27, 2021
Zika virus RNA excretion in sweat with concomitant detection in other body fluid specimensArmando Menezes-Neto, Marcia da Costa Castilho, Guilherme Amaral Calvet, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike GlycoproteinM Gordon Joyce, Rajeshwer S Sankhala, Wei-Hung Chen, et al.
Pageof 14

Showing results (61-70 of 135) with videos related to

Sort By:
Pageof 14
Emerging Infectious Diseases|April 20, 2019
Zika Virus in Rectal Swab SamplesCamila Helena Aguiar Bôtto-Menezes, Armando Menezes Neto, Guilherme Amaral Calvet, et al.
Ebiomedicine|October 4, 2023
Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccineYifan Li, Mélanie Merbah, Suzanne Wollen-Roberts, et al.
Infectious Diseases and Therapy|July 1, 2025
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 TrialOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Vaccine|February 25, 2025
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years oldOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Plos One|March 30, 2021
Clinical laboratory reference values in adults in Kisumu County, Western Kenya; hematology, chemistry and CD4Valentine Sing'oei, Jew Ochola, John Owuoth, et al.
Vaccines|February 24, 2024
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 TrialJuleen Gayed, Oyeniyi Diya, Francine S Lowry, et al.
NPJ Vaccines|December 14, 2021
SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responsesJoshua M Carmen, Shikha Shrivastava, Zhongyan Lu, et al.
Journal of Neuroinflammation|February 8, 2022
Neurocognitive impact of Zika virus infection in adult rhesus macaquesDenise C Hsu, Kesara Chumpolkulwong, Michael J Corley, et al.
Memorias Do Instituto Oswaldo Cruz|January 27, 2021
Zika virus RNA excretion in sweat with concomitant detection in other body fluid specimensArmando Menezes-Neto, Marcia da Costa Castilho, Guilherme Amaral Calvet, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike GlycoproteinM Gordon Joyce, Rajeshwer S Sankhala, Wei-Hung Chen, et al.
Pageof 14